Study on the selective cancer cell killing by resibufogenin

TANG Xin-wei,XIAO Jie,SONG Jian,ZOU Qiang,WANG Rui-xue,LI Yan-qi,YANG Tai
DOI: https://doi.org/10.3969/j.issn.1007-3969.2012.03.007
2012-01-01
Abstract:Background and purpose:Resibufogenin is a major compound of Chinese traditional anticancer drug-toad venom.The previous study had shown that RBG could kill cancer cells but had no toxicity to PBMC.In this study,the selective cancer cells killed by RBG was further investigated.Methods:Toxicity of RBG on Jurkat,Hep3B,PBMC and PHA-stimulated PBMC was analyzed.Cancer cell survival curves were calculated by CCK-8 colorimetric assay.PBMC survival exposed to drug was analyzed by FCM.Results:RBG could obviously inhibit the growth of Jurkat and Hep3B cells.The concentration levels of camptothecin,adriamycin,and etoposide including RBG showed no toxicity to PBMC but have obvious toxicity to PHA stimulated PBMC.Conclusion:RBG like other anticancer drugs targeted on tumor cell proliferation phase.Taken together,the previous study concluded cardiac glycosides selectively kill cancer cell is incorrect.
What problem does this paper attempt to address?